Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban + DAPT vs DAPT in ACS patients after PCI
NCT05638867Phase 4Recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rivaroxaban in acute coronary syndrome (ACS), sponsored by National Center for Cardiovascular Disease. Started Nov 2023; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT05638867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638867.